Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
172 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2016', provides an overview of the Human papillomavirus (HPV) Associated Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Human papillomavirus (HPV) Associated Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Human papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Human papillomavirus (HPV) Associated Cancer - The report reviews pipeline therapeutics for Human papillomavirus (HPV) Associated Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Human papillomavirus (HPV) Associated Cancer therapeutics and enlists all their major and minor projects - The report assesses Human papillomavirus (HPV) Associated Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Human papillomavirus (HPV) Associated Cancer Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Human papillomavirus (HPV) Associated Cancer - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Human papillomavirus (HPV) Associated Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Human Papillomavirus (HPV) Associated Cancer Overview 9 Therapeutics Development 10 Pipeline Products for Human Papillomavirus (HPV) Associated Cancer - Overview 10 Pipeline Products for Human Papillomavirus (HPV) Associated Cancer - Comparative Analysis 11 Human Papillomavirus (HPV) Associated Cancer - Therapeutics under Development by Companies 12 Human Papillomavirus (HPV) Associated Cancer - Therapeutics under Investigation by Universities/Institutes 15 Human Papillomavirus (HPV) Associated Cancer - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Human Papillomavirus (HPV) Associated Cancer - Products under Development by Companies 19 Human Papillomavirus (HPV) Associated Cancer - Products under Investigation by Universities/Institutes 22 Human Papillomavirus (HPV) Associated Cancer - Companies Involved in Therapeutics Development 23 Admedus Ltd 23 Advaxis, Inc. 24 Antigen Express, Inc. 25 Bionor Pharma ASA 26 BioNTech AG 27 Cancer Research Technology Limited 28 Cell Medica Limited 29 Etubics Corporation 30 EyeGene, Inc. 31 Formune S.L. 32 Genexine, Inc. 33 Genticel S.A. 34 iBio, Inc. 35 Immunovaccine, Inc. 36 Inovio Pharmaceuticals, Inc. 37 Inthera Bioscience AG 38 Johnson & Johnson 39 Karyopharm Therapeutics, Inc. 40 Kite Pharma, Inc. 41 MedImmune, LLC 42 Novartis AG 43 Onconova Therapeutics, Inc. 44 Oryx GmbH & Co. KG 45 Profectus BioSciences, Inc. 46 Selecta Biosciences, Inc. 47 Shantha Biotechnics Limited 48 Sirnaomics, Inc. 49 Theravectys SA 50 THEVAX Genetics Vaccine USA Inc 51 Tomegavax, Inc. 52 Transgene SA 53 UbiVac, LLC 54 Vaccibody AS 55 Vault Pharma Inc. 56 Virometix AG 57 ViroStatics srl 58 VLPbio 59 Human Papillomavirus (HPV) Associated Cancer - Therapeutics Assessment 60 Assessment by Monotherapy Products 60 Assessment by Target 61 Assessment by Mechanism of Action 63 Assessment by Route of Administration 65 Assessment by Molecule Type 67 Drug Profiles 69 ABI-1968 - Drug Profile 69 AEH-10p - Drug Profile 70 alpelisib - Drug Profile 71 Antibodies to Target E6 for HPV Associated Cancer - Drug Profile 74 Antibodies to Target E7 for HPV Associated Cancer - Drug Profile 75 BVAC-C - Drug Profile 76 Cellular Immunotherapy for HPV Associated Cancers - Drug Profile 77 Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer - Drug Profile 78 Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer - Drug Profile 80 CerviVax - Drug Profile 82 CMD-004 - Drug Profile 83 DPV-001 - Drug Profile 84 DPXE-7 - Drug Profile 86 EDA-HPVE7 - Drug Profile 87 EG-HPV - Drug Profile 88 Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer - Drug Profile 89 ETBX-041 - Drug Profile 90 GTL-001 - Drug Profile 91 GTL-002 - Drug Profile 94 GX-188E - Drug Profile 95 human papillomavirus (7-valent) vaccine - Drug Profile 97 human papillomavirus [Serotype 16] vaccine - Drug Profile 98 human papillomavirus [serotypes 16] vaccine - Drug Profile 99 human papillomavirus vaccine - Drug Profile 100 human papillomavirus vaccine - Drug Profile 101 human papillomavirus vaccine - Drug Profile 102 human papillomavirus vaccine [types 6, 11, 16, 18] biosimilar - Drug Profile 103 INO-3106 - Drug Profile 104 INO-3112 - Drug Profile 105 Lm-LLO-ISG15 - Drug Profile 107 LN-145 - Drug Profile 109 Monoclonal Antibody to Target E6 and E7 Proteins for Oncology - Drug Profile 111 NIT-02 - Drug Profile 112 NP-001 - Drug Profile 113 PVX-01 - Drug Profile 114 Recombinant Vector Vaccine to Target E7 for HPV Associated Cancers - Drug Profile 115 Recombinant Vector Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile 116 rigosertib sodium - Drug Profile 117 sdCMV-002 - Drug Profile 128 SEL-701 - Drug Profile 129 Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HPV Associated Cancers - Drug Profile 130 Small Molecules for Solid Tumors and HPV Associated Cancer - Drug Profile 131 STP-909 - Drug Profile 132 Subunit Vaccine for HPV Associated Cervical Cancer - Drug Profile 133 Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer - Drug Profile 134 TA-CIN - Drug Profile 135 TG-4001 - Drug Profile 136 TVGV-1 - Drug Profile 138 Vacc-HPV - Drug Profile 139 Vaccine for HIV and HPV Associated Cancer - Drug Profile 140 Vaccine for HPV Associated Cancer - Drug Profile 141 Vaccine for HPV Associated Cancers - Drug Profile 142 Vaccine for HPV Associated Cervical Cancer - Drug Profile 143 Vaccine for HPV Associated Cervical Cancer - Drug Profile 144 Vaccine for HPV Associated Cervical Cancer - Drug Profile 145 Vaccine for HPV Associated Skin Cancer - Drug Profile 146 Vaccine for Human papillomavirus Associated Cervical Cancer - Drug Profile 147 VB-1016 - Drug Profile 148 verdinexor - Drug Profile 150 VGX-3100 - Drug Profile 151 Vicoryx - Drug Profile 154 VMT-2 - Drug Profile 155 VPI-241 - Drug Profile 156 Vvax-001 - Drug Profile 157 Human Papillomavirus (HPV) Associated Cancer - Dormant Projects 158 Human Papillomavirus (HPV) Associated Cancer - Product Development Milestones 160 Featured News & Press Releases 160 Appendix 167 Methodology 167 Coverage 167 Secondary Research 167 Primary Research 167 Expert Panel Validation 167 Contact Us 167 Disclaimer 168
List of Tables
Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H2 2016 14 Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer - Comparative Analysis, H2 2016 15 Number of Products under Development by Companies, H2 2016 16 Number of Products under Development by Companies, H2 2016 (Contd..1) 17 Number of Products under Development by Companies, H2 2016 (Contd..2) 18 Number of Products under Investigation by Universities/Institutes, H2 2016 19 Comparative Analysis by Late Stage Development, H2 2016 20 Comparative Analysis by Clinical Stage Development, H2 2016 21 Comparative Analysis by Early Stage Development, H2 2016 22 Products under Development by Companies, H2 2016 23 Products under Development by Companies, H2 2016 (Contd..1) 24 Products under Development by Companies, H2 2016 (Contd..2) 25 Products under Investigation by Universities/Institutes, H2 2016 26 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Admedus Ltd, H2 2016 27 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Advaxis, Inc., H2 2016 28 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Antigen Express, Inc., H2 2016 29 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Bionor Pharma ASA, H2 2016 30 Human Papillomavirus (HPV) Associated Cancer - Pipeline by BioNTech AG, H2 2016 31 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Cancer Research Technology Limited, H2 2016 32 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Cell Medica Limited, H2 2016 33 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Etubics Corporation, H2 2016 34 Human Papillomavirus (HPV) Associated Cancer - Pipeline by EyeGene, Inc., H2 2016 35 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Formune S.L., H2 2016 36 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Genexine, Inc., H2 2016 37 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Genticel S.A., H2 2016 38 Human Papillomavirus (HPV) Associated Cancer - Pipeline by iBio, Inc., H2 2016 39 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Immunovaccine, Inc., H2 2016 40 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016 41 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Inthera Bioscience AG, H2 2016 42 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Johnson & Johnson, H2 2016 43 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 44 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Kite Pharma, Inc., H2 2016 45 Human Papillomavirus (HPV) Associated Cancer - Pipeline by MedImmune, LLC, H2 2016 46 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Novartis AG, H2 2016 47 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Onconova Therapeutics, Inc., H2 2016 48 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Oryx GmbH & Co. KG, H2 2016 49 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Profectus BioSciences, Inc., H2 2016 50 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Selecta Biosciences, Inc., H2 2016 51 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Shantha Biotechnics Limited, H2 2016 52 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Sirnaomics, Inc., H2 2016 53 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Theravectys SA, H2 2016 54 Human Papillomavirus (HPV) Associated Cancer - Pipeline by THEVAX Genetics Vaccine USA Inc, H2 2016 55 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Tomegavax, Inc., H2 2016 56 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Transgene SA, H2 2016 57 Human Papillomavirus (HPV) Associated Cancer - Pipeline by UbiVac, LLC, H2 2016 58 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Vaccibody AS, H2 2016 59 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Vault Pharma Inc., H2 2016 60 Human Papillomavirus (HPV) Associated Cancer - Pipeline by Virometix AG, H2 2016 61 Human Papillomavirus (HPV) Associated Cancer - Pipeline by ViroStatics srl, H2 2016 62 Human Papillomavirus (HPV) Associated Cancer - Pipeline by VLPbio, H2 2016 63 Assessment by Monotherapy Products, H2 2016 64 Number of Products by Stage and Target, H2 2016 66 Number of Products by Stage and Mechanism of Action, H2 2016 68 Number of Products by Stage and Route of Administration, H2 2016 70 Number of Products by Stage and Molecule Type, H2 2016 72 Human Papillomavirus (HPV) Associated Cancer - Dormant Projects, H2 2016 162 Human Papillomavirus (HPV) Associated Cancer - Dormant Projects (Contd..1), H2 2016 163
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
